Naresh Dhanavath, Priya Bisht, Mohini Santosh Jamadade, Krishna Murti, Pranay Wal, Nitesh Kumar
McKinnon C.; Nandhabalan M.; Murray S.A.; Plaha P.; Glioblastoma: Clinical presentation, diagnosis, and management. BMJ 2021,374(n1560)
[DOI:
10.1136/bmj.n1560]
Grochans S.; Cybulska A.M.; Simińska D.; Korbecki J.; Kojder K.; Chlubek D.; Baranowska-Bosiacka I.; Epidemiology of glioblastoma multiforme–literature review. Cancers (Basel) 2022,14(10),2412
[DOI:
10.3390/cancers14102412]
Naim A.; ouazzani, H.; Rafii, S.; Azhari, A.; Badou, A. Epidemiology, treatment, and evolution of glioblastoma in a low-income country: Moroccan experience. J Cancer Sci Clin Ther 2023,7(1),16-20
[DOI:
10.26502/jcsct.5079187]
Hanif F.; Muzaffar K.; Perveen K.; Malhi S.M.; Simjee ShU.; Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 2017,18(1),3-9
[PMID:
28239999]
Singh N.; Miner A.; Hennis L.; Mittal S.; Mechanisms of temozolomide resistance in glioblastoma - A comprehensive review. Cancer Drug Resist 2021,4(1),17
[DOI:
10.20517/cdr.2020.79]
Delello Di Filippo L.; Hofstätter Azambuja J.; Paes Dutra J.A.; Tavares Luiz M.; Lobato Duarte J.; Nicoleti L.R.; Olalla Saad S.T.; Chorilli M.; Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. Eur J Pharm Biopharm 2021,168,76-89
[DOI:
10.1016/j.ejpb.2021.08.011]
Teraiya M.; Perreault H.; Chen V.C.; An overview of glioblastoma multiforme and temozolomide resistance: Can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance? Front Oncol 2023,13,1166207
[DOI:
10.3389/fonc.2023.1166207]
Bisht P.; Kumar V.U.; Pandey R.; Velayutham R.; Kumar N.; Role of PARP inhibitors in glioblastoma and perceiving challenges as well as strategies for successful clinical development. Front Pharmacol 2022,13,939570
[DOI:
10.3389/fphar.2022.939570]
Zhang J.; Stevens M.F.G.; Bradshaw T.D.; Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol 2012,5(1),102-114
[DOI:
10.2174/1874467211205010102]
Sim H.W.; Galanis E.; Khasraw M.; PARP inhibitors in glioma: A review of therapeutic opportunities. Cancers (Basel) 2022,14(4),1003
[DOI:
10.3390/cancers14041003]
Montaldi A.; Lima S.; Godoy P.; Xavier D.; Sakamoto-Hojo E.; PARP 1 inhibition sensitizes temozolomide treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Oncol Rep 2020,44(5),2275-2287
[DOI:
10.3892/or.2020.7756]
Silpa N.; Qiu-Xu T.; Jagadish K.; Jingquan W.; Yehuda G.A.; Charles R.A.J.; Zhe-Sheng C.; Poly (ADP-ribose) polymerase (PARP) inhibitors as chemosensitizing compounds for the treatment of drug resistant cancers. J Mol Clin Med 2019,2(3),55-67
[DOI:
10.31083/j.jmcm.2019.03.0303]
Thorsell A.G.; Ekblad T.; Karlberg T.; Löw M.; Pinto A.F.; Trésaugues L.; Moche M.; Cohen M.S.; Schüler H.; Structural basis for potency and promiscuity in poly (ADP-ribose) polymerase (PARP) and tankyrase inhibitors. J Med Chem 2017,60(4),1262-1271
[DOI:
10.1021/acs.jmedchem.6b00990]
Friedlander M.; Gebski V.; Gibbs E.; Davies L.; Bloomfield R.; Hilpert F.; Wenzel L.B.; Eek D.; Rodrigues M.; Clamp A.; Penson R.T.; Provencher D.; Korach J.; Huzarski T.; Vidal L.; Salutari V.; Scott C.; Nicoletto M.O.; Tamura K.; Espinoza D.; Joly F.; Pujade-Lauraine E.; Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): A placebo-controlled, phase 3 randomised trial. Lancet Oncol 2018,19(8),1126-1134
[DOI:
10.1016/S1470-2045(18)30343-7]
Rolfo C.; de Vos-Geelen J.; Isambert N.; Molife L.R.; Schellens J.H.M.; De Grève J.; Dirix L.; Grundtvig-Sørensen P.; Jerusalem G.; Leunen K.; Mau-Sørensen M.; Plummer R.; Learoyd M.; Bannister W.; Fielding A.; Ravaud A.; Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment. Clin Pharmacokinet 2019,58(9),1165-1174
[DOI:
10.1007/s40262-019-00754-4]
Ledermann J.A.; Pujade-Lauraine E.; Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol 2019,11
[DOI:
10.1177/1758835919849753]
Pujade-Lauraine E.; Ledermann J.A.; Selle F.; Gebski V.; Penson R.T.; Oza A.M.; Korach J.; Huzarski T.; Poveda A.; Pignata S.; Friedlander M.; Colombo N.; Harter P.; Fujiwara K.; Ray-Coquard I.; Banerjee S.; Liu J.; Lowe E.S.; Bloomfield R.; Pautier P.; Korach J.; Huzarski T.; Byrski T.; Pautier P.; Friedlander M.; Harter P.; Colombo N.; Pignata S.; Scambia G.; Nicoletto M.; Nussey F.; Clamp A.; Penson R.; Oza A.; Poveda Velasco A.; Rodrigues M.; Lotz J-P.; Selle F.; Ray-Coquard I.; Provencher D.; Prat Aparicio A.; Vidal Boixader L.; Scott C.; Tamura K.; Yunokawa M.; Lisyanskaya A.; Medioni J.; Pécuchet N.; Dubot C.; de la Motte Rouge T.; Kaminsky M-C.; Weber B.; Lortholary A.; Parkinson C.; Ledermann J.; Williams S.; Banerjee S.; Cosin J.; Hoffman J.; Penson R.; Plante M.; Covens A.; Sonke G.; Joly F.; Floquet A.; Banerjee S.; Hirte H.; Amit A.; Park-Simon T-W.; Matsumoto K.; Tjulandin S.; Kim J.H.; Gladieff L.; Sabbatini R.; O’Malley D.; Timmins P.; Kredentser D.; Laínez Milagro N.; Barretina Ginesta M.P.; Tibau Martorell A.; Gómez de Liaño Lista A.; Ojeda González B.; Mileshkin L.; Mandai M.; Boere I.; Ottevanger P.; Nam J-H.; Filho E.; Hamizi S.; Cognetti F.; Warshal D.; Dickson-Michelson E.; Kamelle S.; McKenzie N.; Rodriguez G.; Armstrong D.; Chalas E.; Celano P.; Behbakht K.; Davidson S.; Welch S.; Helpman L.; Fishman A.; Bruchim I.; Sikorska M.; Słowińska A.; Rogowski W.; Bidziński M.; Śpiewankiewicz B.; Casado Herraez A.; Mendiola Fernández C.; Gropp-Meier M.; Saito T.; Takehara K.; Enomoto T.; Watari H.; Choi C.H.; Kim B-G.; Kim J.W.; Hegg R.; Vergote I.; Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017,18(9),1274-1284
[DOI:
10.1016/S1470-2045(17)30469-2]
Tomar M.S.; Kumar A.; Srivastava C.; Shrivastava A.; Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer 2021,1876(2),188616
[DOI:
10.1016/j.bbcan.2021.188616]
Yoshimoto K.; Mizoguchi M.; Hata N.; Murata H.; Hatae R.; Amano T.; Nakamizo A.; Sasaki T.; Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol 2012,2,186
[DOI:
10.3389/fonc.2012.00186]
Kitange G.J.; Carlson B.L.; Schroeder M.A.; Grogan P.T.; Lamont J.D.; Decker P.A.; Wu W.; James C.D.; Sarkaria J.N.; Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncol 2009,11(3),281-291
[DOI:
10.1215/15228517-2008-090]
Cropper J.D.; Alimbetov D.S.; Brown K.T.G.; Likhotvorik R.I.; Robles A.J.; Guerra J.T.; He B.; Chen Y.; Kwon Y.; Kurmasheva R.T.; PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair. J Hematol Oncol 2022,15(1),146
[DOI:
10.1186/s13045-022-01367-4]
Tang J.; Svilar D.; Trivedi R.N.; Wang X.; Goellner E.M.; Moore B.; Hamilton R.L.; Banze L.A.; Brown A.R.; Sobol R.W.; N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro-oncol 2011,13(5),471-486
[DOI:
10.1093/neuonc/nor011]
Messaoudi K.; Clavreul A.; Lagarce F.; Toward an effective strategy in glioblastoma treatment. Part I: Resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today 2015,20(7),899-905
[DOI:
10.1016/j.drudis.2015.02.011]
Kamaletdinova T.; Fanaei-Kahrani Z.; Wang Z.Q.; The enigmatic function of PARP1: From parylation activity to PAR readers. Cells 2019,8(12),1625
[DOI:
10.3390/cells8121625]
Rouleau M.; Patel A.; Hendzel M.J.; Kaufmann S.H.; Poirier G.G.; PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010,10(4),293-301
[DOI:
10.1038/nrc2812]
Zhang J.; Zhang J.; Li H.; Chen L.; Yao D.; Dual-target inhibitors of PARP1 in cancer therapy: A drug discovery perspective. Drug Discov Today 2023,28(7),103607
[DOI:
10.1016/j.drudis.2023.103607]
Wu S.; Li X.; Gao F.; de Groot J.F.; Koul D.; Yung W.K.A.; PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro-oncol 2021,23(6),920-931
[DOI:
10.1093/neuonc/noab003]
Robson M.; Im S.A.; Senkus E.; Xu B.; Domchek S.M.; Masuda N.; Delaloge S.; Li W.; Tung N.; Armstrong A.; Wu W.; Goessl C.; Runswick S.; Conte P.; Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017,377(6),523-533
[DOI:
10.1056/NEJMoa1706450]
Chen Y.; Zhang L.; Hao Q.; Olaparib: A promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 2013,288(2),367-374
[DOI:
10.1007/s00404-013-2856-2]
Kim G.; Ison G.; McKee A.E.; Zhang H.; Tang S.; Gwise T.; Sridhara R.; Lee E.; Tzou A.; Philip R.; Chiu H.J.; Ricks T.K.; Palmby T.; Russell A.M.; Ladouceur G.; Pfuma E.; Li H.; Zhao L.; Liu Q.; Venugopal R.; Ibrahim A.; Pazdur R.; FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 2015,21(19),4257-4261
[DOI:
10.1158/1078-0432.CCR-15-0887]
Bixel K.; Hays J.; Olaparib in the management of ovarian cancer. Pharm Genomics Pers Med 2015,8,127-135
[DOI:
10.2147/PGPM.S62809]
Yang Y.G.; Cortes U.; Patnaik S.; Jasin M.; Wang Z.Q.; Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 2004,23(21),3872-3882
[DOI:
10.1038/sj.onc.1207491]
Mateo J.; Carreira S.; Sandhu S.; Miranda S.; Mossop H.; Perez-Lopez R.; Nava Rodrigues D.; Robinson D.; Omlin A.; Tunariu N.; Boysen G.; Porta N.; Flohr P.; Gillman A.; Figueiredo I.; Paulding C.; Seed G.; Jain S.; Ralph C.; Protheroe A.; Hussain S.; Jones R.; Elliott T.; McGovern U.; Bianchini D.; Goodall J.; Zafeiriou Z.; Williamson C.T.; Ferraldeschi R.; Riisnaes R.; Ebbs B.; Fowler G.; Roda D.; Yuan W.; Wu Y.M.; Cao X.; Brough R.; Pemberton H.; A’Hern R.; Swain A.; Kunju L.P.; Eeles R.; Attard G.; Lord C.J.; Ashworth A.; Rubin M.A.; Knudsen K.E.; Feng F.Y.; Chinnaiyan A.M.; Hall E.; de Bono J.S.; DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015,373(18),1697-1708
[DOI:
10.1056/NEJMoa1506859]
Hwang K.; Lee J-H.; Kim S.H.; Go K-O.; Ji S.Y.; Han J.H.; Kim C-Y.; The combination PARP inhibitor olaparib with temozolomide in an experimental glioblastoma model. In Vivo 2021,35(4),2015-2023
[DOI:
10.21873/invivo.12470]
Valiakhmetova A.; Gorelyshev S.; Konovalov A.; Trunin Y.; Savateev A.; Kram D.E.; Severson E.; Hemmerich A.; Edgerly C.; Duncan D.; Britt N.; Huang R.S.P.; Elvin J.; Miller V.; Ross J.S.; Gay L.; McCorkle J.; Rankin A.; Erlich R.L.; Chudnovsky Y.; Ramkissoon S.H.; Treatment of pediatric glioblastoma with combination olaparib and temozolomide demonstrates 2‐year durable response. Oncologist 2020,25(2),e198-e202
[DOI:
10.1634/theoncologist.2019-0603]
Dungey F.A.; Löser D.A.; Chalmers A.J.; Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: Mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008,72(4),1188-1197
[DOI:
10.1016/j.ijrobp.2008.07.031]
van Vuurden D.G.; Hulleman E.; Meijer O.L.M.; Wedekind L.E.; Kool M.; Witt H.; Vandertop W.P.; Würdinger T.; Noske D.P.; Kaspers G.J.L.; Cloos J.; PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011,2(12),984-996
[DOI:
10.18632/oncotarget.362]
Karpel-Massler G.; Pareja F.; Aimé P.; Shu C.; Chau L.; Westhoff M.A.; Halatsch M.E.; Crary J.F.; Canoll P.; Siegelin M.D.; PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. PLoS One 2014,9(12),e114583
[DOI:
10.1371/journal.pone.0114583]
Hanna C.; Kurian K.M.; Williams K.; Watts C.; Jackson A.; Carruthers R.; Strathdee K.; Cruickshank G.; Dunn L.; Erridge S.; Godfrey L.; Jefferies S.; McBain C.; Sleigh R.; McCormick A.; Pittman M.; Halford S.; Chalmers A.J.; Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: Results of the phase I OPARATIC trial. Neuro-oncol 2020,22(12),1840-1850
[DOI:
10.1093/neuonc/noaa104]
Navarro-Carrasco E.; Lazo P.A.; VRK1 depletion facilitates the synthetic lethality of temozolomide and olaparib in glioblastoma cells. Front Cell Dev Biol 2021,9,683038
[DOI:
10.3389/fcell.2021.683038]
Chalmers A.J.; Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2. J Clin Oncol 2018,36(Suppl 15)
[DOI:
10.1200/JCO.2018.36.15_suppl.2018]
Rottenberg S.; Jaspers J.E.; Kersbergen A.; van der Burg E.; Nygren A.O.H.; Zander S.A.L.; Derksen P.W.B.; de Bruin M.; Zevenhoven J.; Lau A.; Boulter R.; Cranston A.; O’Connor M.J.; Martin N.M.B.; Borst P.; Jonkers J.; High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008,105(44),17079-17084
[DOI:
10.1073/pnas.0806092105]
Li H.; Liu Z.Y.; Wu N.; Chen Y.C.; Cheng Q.; Wang J.; PARP inhibitor resistance: The underlying mechanisms and clinical implications. Mol Cancer 2020,19(1),107
[DOI:
10.1186/s12943-020-01227-0]
Ito S.; Murphy C.G.; Doubrovina E.; Jasin M.; Moynahan M.E.; PARP inhibitors in clinical use induce genomic instability in normal human cells. PLoS One 2016,11(7),e0159341
[DOI:
10.1371/journal.pone.0159341]
Agarwal S.; Mittapalli R.K.; Zellmer D.M.; Gallardo J.L.; Donelson R.; Seiler C.; Decker S.A.; SantaCruz K.S.; Pokorny J.L.; Sarkaria J.N.; Elmquist W.F.; Ohlfest J.R.; Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: Broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther 2012,11(10),2183-2192
[DOI:
10.1158/1535-7163.MCT-12-0552]
Gupta S.K.; Smith E.J.; Mladek A.C.; Tian S.; Decker P.A.; Kizilbash S.H.; Kitange G.J.; Sarkaria J.N.; PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: Impact of blood-brain barrier and molecular heterogeneity. Front Oncol 2019,8,670
[DOI:
10.3389/fonc.2018.00670]
Saran F.; James A.; McBain C.; Jefferies S.; Harris F.; Cseh A.; Pemberton K.; Schaible J.; Bender S.; Brada M.; ACTR-38. A phase I trial of afatinib and radiotherapy (rt) with or without temozolomide (tmz) in patients with newly diagnosed glioblastoma (GBM). Neuro-oncol 2018,20(Suppl. 6),vi20
[DOI:
10.1093/neuonc/noy148.071]
Berens M.E.; Giese A.; “...those left behind.” Biology and oncology of invasive glioma cells. Neoplasia 1999,1(3),208-219
[DOI:
10.1038/sj.neo.7900034]
Pitz M.W.; Desai A.; Grossman S.A.; Blakeley J.O.; Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 2011,104(3),629-638
[DOI:
10.1007/s11060-011-0564-y]
Levin V.A.; Patlak C.S.; Landahl H.D.; Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm 1980,8(3),257-296
[DOI:
10.1007/BF01059646]
Blakeley J.O.; Olson J.; Grossman S.A.; He X.; Weingart J.; Supko J.G.; Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: A microdialysis study. J Neurooncol 2009,91(1),51-58
[DOI:
10.1007/s11060-008-9678-2]
Gupta S.K.; Mladek A.C.; Carlson B.L.; Boakye-Agyeman F.; Bakken K.K.; Kizilbash S.H.; Schroeder M.A.; Reid J.; Sarkaria J.N.; Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 2014,20(14),3730-3741
[DOI:
10.1158/1078-0432.CCR-13-3446]
Kizilbash S.H.; Gupta S.K.; Chang K.; Kawashima R.; Parrish K.E.; Carlson B.L.; Bakken K.K.; Mladek A.C.; Schroeder M.A.; Decker P.A.; Kitange G.J.; Shen Y.; Feng Y.; Protter A.A.; Elmquist W.F.; Sarkaria J.N.; Restricted delivery of talazoparib across the blood–brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma. Mol Cancer Ther 2017,16(12),2735-2746
[DOI:
10.1158/1535-7163.MCT-17-0365]
Parrish K.E.; Cen L.; Murray J.; Calligaris D.; Kizilbash S.; Mittapalli R.K.; Carlson B.L.; Schroeder M.A.; Sludden J.; Boddy A.V.; Agar N.Y.R.; Curtin N.J.; Elmquist W.F.; Sarkaria J.N.; Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system. Mol Cancer Ther 2015,14(12),2735-2743
[DOI:
10.1158/1535-7163.MCT-15-0553]
Gupta S.K.; Kizilbash S.H.; Carlson B.L.; Mladek A.C.; Boakye-Agyeman F.; Bakken K.K.; Pokorny J.L.; Schroeder M.A.; Decker P.A.; Cen L.; Eckel-Passow J.E.; Sarkar G.; Ballman K.V.; Reid J.M.; Jenkins R.B.; Verhaak R.G.; Sulman E.P.; Kitange G.J.; Sarkaria J.N.; Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma. J Natl Cancer Inst 2015,108(5),djv369
[DOI:
10.1093/jnci/djv369]
Sargazi S.; Mukhtar M.; Rahdar A.; Barani M.; Pandey S.; Díez-Pascual A.; Active targeted nanoparticles for delivery of poly (ADP-ribose) polymerase (PARP) inhibitors: A preliminary review. Int J Mol Sci 2021,22(19),10319
[DOI:
10.3390/ijms221910319]
Mensah L.B.; Morton S.W.; Li J.; Xiao H.; Quadir M.A.; Elias K.M.; Penn E.; Richson A.K.; Ghoroghchian P.P.; Liu J.; Hammond P.T.; Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer. Bioeng Transl Med 2019,4(2),e10131
[DOI:
10.1002/btm2.10131]
Baldwin P.; Tangutoori S.; Sridhar S.; In vitro analysis of PARP inhibitor nanoformulations. Int J Nanomedicine 2018,13(Suppl.),59-61
[DOI:
10.2147/IJN.S124992]
Zhang D.; Baldwin P.; Leal A.S.; Carapellucci S.; Sridhar S.; Liby K.T.; A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics 2019,9(21),6224-6238
[DOI:
10.7150/thno.36281]
Patel P.; Combined nanoparticle delivery of PARP and DNA-PK inhibition for multiple myeloma. Blood 2017,130,1809
Baldwin P.; Ohman A.W.; Tangutoori S.; Dinulescu D.M.; Sridhar S.; Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. Int J Nanomedicine 2018,13,8063-8074
[DOI:
10.2147/IJN.S186881]
Pathade A.D.; Kommineni N.; Bulbake U.; Thummar M.M.; Samanthula G.; Khan W.; Preparation and comparison of oral bioavailability for different nanoformulations of olaparib. AAPS PharmSciTech 2019,20(7),276
[DOI:
10.1208/s12249-019-1468-y]
McCrorie P.; Mistry J.; Taresco V.; Lovato T.; Fay M.; Ward I.; Ritchie A.A.; Clarke P.A.; Smith S.J.; Marlow M.; Rahman R.; Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours. Eur J Pharm Biopharm 2020,157,108-120
[DOI:
10.1016/j.ejpb.2020.10.005]
Fulton B.; Short S.C.; James A.; Nowicki S.; McBain C.; Jefferies S.; Kelly C.; Stobo J.; Morris A.; Williamson A.; Chalmers A.J.; PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clin Transl Radiat Oncol 2018,8,12-16
[DOI:
10.1016/j.ctro.2017.11.003]
